Alpha Beta Arteether
Semi-synthetic artemisinin derivative in USP-aligned grade, traded as an oily solution for IM injectable manufacturing. Sourced for severe and cerebral malaria treatment, typically in 30:70 alpha:beta isomer ratio.
Pharmaceutical & Life Science Solutions
Artemisinin derivatives, quinoline alkaloids, and cinchona-based APIs for ACT and parenteral malaria regimens. Supplied in USP/EP/BP grade to manufacturers serving endemic and non-endemic export markets.
Semi-synthetic artemisinin derivative in USP-aligned grade, traded as an oily solution for IM injectable manufacturing. Sourced for severe and cerebral malaria treatment, typically in 30:70 alpha:beta isomer ratio.
4-aminoquinoline antimalarial supplied as free base (86-42-0) and hydrochloride salt (69-44-3) — USP/EP/BP grade — for oral tablet and suspension manufacturing. Sourced for ACT combination with artesunate against P. falciparum and P. vivax.
Methyl ether derivative of artemisinin in USP/EP/BP/JP grade for oral and injectable formulation manufacturing. Core API in artemether-lumefantrine fixed-dose ACT for multi-drug-resistant P. falciparum.
Water-soluble artemisinin derivative traded in plain grade for oral/rectal formulations and sterile grade (USP <797> processed) for IV/IM injectable manufacturing. Same active compound across both grades — used for severe and uncomplicated malaria.
Classic 4-aminoquinoline antimalarial in USP/EP/BP grade for oral tablet manufacturing. Sourced for prophylaxis and treatment of chloroquine-susceptible P. vivax and P. falciparum strains.
Active artemisinin metabolite in USP/EP grade for oral tablet and capsule formulation manufacturing. Supplied both as the reduction intermediate behind artemether/artesunate metabolism and for standalone ACT formulations.
Aryl amino alcohol antimalarial in USP/EP/BP/IP grade for fixed-dose combination tablet manufacturing alongside artemether. Core partner compound in WHO-recommended ACT regimens for P. falciparum.
Quinolinemethanol antimalarial supplied as hydrochloride salt — USP grade — for oral tablet manufacturing. Sourced for prophylaxis and treatment of multi-drug-resistant P. falciparum malaria.
8-aminoquinoline radical curative agent in USP/EP/BP grade for oral tablet manufacturing. Sourced for hepatic hypnozoite elimination in P. vivax and P. ovale relapse prevention.
Water-soluble cinchona alkaloid salt in USP/EP/BP grade for injectable solution manufacturing. Sourced for parenteral treatment of severe malaria where oral administration is not feasible.
Cinchona alkaloid hydrochloride dihydrate in USP/EP/BP grade for injectable and oral formulation manufacturing. Supplied for severe malaria protocols requiring parenteral or oral alkaloid therapy.
Cinchona bark-derived alkaloid sulfate salt in USP/EP/BP grade for oral tablet and suspension manufacturing. Sourced for uncomplicated and severe malaria treatment in combination regimens.